drugset / Trial / NCT00053703

Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)

NCT00053703

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety and efficacy of risperidone (Risperdal®), olanzapine (Zyprexa®), and molindone (Moban®) for the treatment of children and adolescents with schizophrenia or schizoaffective disorder.

Timeline

Start
2002-02
Primary completion
2007-05
Completion
2007-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Molindone Small molecule 10 mg Oral
Comparator Molindone Small molecule 140 mg Oral
Comparator Olanzapine Small molecule 5 mg Oral
Comparator Olanzapine Small molecule 20 mg Oral
Comparator Risperidone Other / unclassified 0.5 mg Oral
Comparator Risperidone Other / unclassified 6 mg Oral

Indications